Opposing pro-and anti-apoptotic actions of TRAIL and the inhibitors of apoptosis (IAPs) contribute to the cell's decision to survive or die. We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NFkB-dependent expression of both pro-and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Inhibition of NF-kB activation in H157 cells in response to genotoxin resulted in loss of cell surface expression of TRAIL and DR5, aggressive growth and chemotherapy resistance of tumors in nude mice. Similar to the paracrine TRAIL response in H157 cells, the sensitivity of normal lung and breast epithelium and carcinomas to undergo genotoxin-induced apoptosis correlates strongly with cell surface expression of TRAIL. Suppression of TRAIL signaling by expression of the TRAIL decoy receptor, DcR1, confers chemo-resistance to cancer cells. These ®ndings demonstrate that TRAIL signaling via its death receptors is a signi®cant contributor to genotoxininduced apoptosis in human epithelial carcinomas.
Introduction
Apoptosis is characterized as being initiated either by death receptor activation or mitochondrial changes mediated by Bcl-2 family members (Yang et al., 1997) . Oligomerization of death receptors such as Fas or DR4 and DR5 upon binding FasL or TRAIL leads to caspase 8 activation (Muzio et al., 1996) . Activation of pro-apoptotic Bcl-2 family proteins (Bad, Bid, Bax, Bak) results in mitochondrial membrane pore formation, loss of membrane potential and the release of cytochrome c and other mitochondrial proteins (Jurgensmeier et al., 1998; Li et al., 1998; Luo et al., 1998; Zha et al., 1996) . Apaf-1 binding of released cytochrome c leads to caspase 9 activation (Zou et al., 1999) . Both caspase 8 and caspase 9 can activate caspase 3 whose activation is generally considered the irreversible commitment to apoptosis.
Cytokines such as FasL and TRAIL trigger the apoptosis module using death receptors as their entry point by activating caspase 8 (Chaudhary et al., 1997; Schneider et al., 1997) . Toxins such as antimycin A appear to bind to the BH3 domain of Bcl-2 and Bcl-X L and initiate apoptosis by in¯uencing mitochondrial pore formation and membrane potential (Tzung et al., 2001) . In contrast to the selective actions of FasL, TRAIL and antimycin A, other apoptotic stimuli such as genotoxins can activate apoptosis via both death receptors and regulation of Bcl-2 family proteins (Sun et al., 1999) . Genotoxins stimulate mitochondrial cytochrome c release via regulation of Bcl-2 and induce the expression of both FasL and TRAIL in dierent cell types (Ashkenazi and Dixit, 1999; Kasibhatla et al., 1998; Kaufmann and Earnshaw, 2000) . The relative contribution of Bcl-2 family proteins and death receptors in genotoxin-induced apoptosis appears to vary depending on the tumor origin and genotoxin.
It is apparent that changes in the expression of death receptors, their ligands and the Bcl-2 family proteins can alter the apoptotic potential of cells. Altered expression or mutation of these proteins provide a survival advantage to tumor cells by down-regulating the entry points that control the activation of apoptosis. We have found with lung and breast-derived epithelial cells, there is a strong correlation between the magnitude of genotoxin-stimulated apoptosis and the expression of TRAIL. Expression of TRAIL and its death receptor, DR5, is regulated in an NF-kB dependent mechanism Ravi et al., 2001) . The genotoxins etoposide and doxorubicin strongly activate NF-kB. In concert with controlling TRAIL/DR5 expression, NF-kB regulates the expres-sion of several anti-apoptotic proteins. This orchestrated response of pro-apoptotic and anti-apoptotic proteins determines the fate of cells to a genotoxic stress. TRAIL is generally able to overcome the antiapoptotic gene induction in epithelial cells. However, when the TRAIL response system is inhibited, chemoresistance and the NF-kB dependent anti-apoptotic response prevail. Cumulatively, our ®ndings indicate that inhibition of TRAIL signaling is a mechanism for epithelial-derived carcinomas to escape apoptosis in response to genotoxins.
Results

NF-kB activity is necessary for the apoptotic response to etoposide in lung and breast cancer cells
In H157 lung squamous carcinoma the expression of dominant negative IkBa (DNIkBa) inhibits genotoxininduced apoptosis ( Figure 1a ). To de®ne the importance of NF-kB in etoposide-induced apoptosis, wild type (WT) H157 cells and DNIkBa H157 cells were treated with etoposide, and apoptosis was quantitated by acridine orange. Basal levels of apoptosis in unstimulated WT H157 cells was approximately 5+1.6% and increased to 31+2.1% and 42+4.7% with 48 h exposure to 30 and 100 mM etoposide, respectively ( Figure 1a ). Apoptosis in unstimulated DNIkBa H157 cells was comparable to WT H157 at 6+2%. With 30 mM etoposide, the apoptotic response was suppressed 40% or greater in DNIkBa relative to WT H157 cells (from 31+2.1% in WT H157 to 17+6.3% for DNIkBa H157 cells seen in Figure 1a , P50.005). Similarly, the 42+4.7% apoptotic cells observed with 100 mM etoposide treatment for 24 h in WT H157 cells decreased to 20+4.2% in DNIkBa H157 cells (P50.005). These studies demonstrate that NF-kB activity is required for maximal apoptotic response to etoposide insult in H157 carcinoma cells.
We have observed a similar pro-apoptotic function for NF-kB in other carcinomas from breast and lung. As shown in Figure 1a , ZR-75-1 breast adenocarcinoma cells behave similarly to H157 cells in that DNIkBa inhibits doxorubicin-induced apoptosis. The apoptotic index of WT ZR-75-1 cells rose from 4+1% to 14+3% with 100 nM doxorubicin and 48+6% with 1 mM doxorubicin treatment for 48 h. The stable expression of DNIkBa in ZR-75-1 cells did not change basal apoptosis levels of 4+1%. Forty-eight hour treatment of the DNIkBa ZR-75-1 cells with 100 nM doxorubicin did not induce apoptosis (4+1%, P50.005 vs WT) while 1 mM doxorubicin yielded only 20% of apoptosis found in WT cells (13+3%, P50.005 vs WT).
These observations in combination with the role of NF-kB in regulating TRAIL expression (Ravi et al., 2001) , led us to examine the role of NF-kB signaling and TRAIL in the control of genotoxin-induced apoptosis in human carcinoma cells. The DNIkBa mutant protein we have used in our studies contains serine to alanine conversions at residues 32 and 36 that abolish the ability of IKKa to phosphorylate these sites. This prevents ubiquitination and degradation of mutant IkBa and subsequent dissociation and nuclear translocation of NF-kB. The inhibition of genotoxin-induced apoptosis was observed in H157 cells stably expressing DNIkBa following transfection and drug selection or acutely after infection with adenovirus encoding DNIkBa (not shown). Because similar results were seen for genotoxin resistance when DNIkBa was expressed by stable transfection or acute adenovirus infection we chose to use stably expressing DNIkBa H157 cells for further study in vitro and in vivo.
To con®rm the dominant negative property of the IkBa mutant, we demonstrated H157 cells expressing DNIkBa fail to stimulate NF-kB DNA binding activity relative to wild type H157 cells following treatment with phorbol ester (PMA) (Figure 1b ) or etoposide ( Figure 1c ). Inhibition of NF-kB DNA binding activity in response to PMA by expression of DNIkBa is speci®c, as AP-1 DNA binding activity remains intact in the same nuclear extracts. For etoposide treatment, both WT and DNIkBa H157 cells were treated with genotoxin for 12 and 24 h (Figure 1b) . NF-kB DNA binding activity is induced following treatment of H157 cells for 12 and 24 h with etoposide, while DNIkBa H157 nuclear extracts show no increase in NF-kB DNA binding activity. Etoposide treatment of WT H157 cells also resulted in decreased levels of IkBa protein detected by immunoblotting, re¯ective of the phosphorylation, ubiquitination, and protein degradation of IkB that allows nuclear translocation and DNA binding of NF-kB (Figure 1d ). DNIkBa H157 cells retain stable and consistent cytosolic levels of IkB protein despite treatment with etoposide. These assays con®rm that DNIkBa eectively abolishes the stimulation of NF-kB activity, preventing transcriptional activation of NF-kB target genes.
To assess further the biologic implications of NFkB inhibition, WT and DNIkBa H157 cells were examined for tumorigenic potential in nude mouse xenografts. 1610 6 WT H157 or DNIkBa H157 cells were injected into nude mice, and tumor volumes were followed for 31 days at which time tumor mass necessitated animal sacri®ce. WT and DNIkBa H157 mouse xenografts grew comparably until day 17, when separation of tumor growth curves became apparent (Figure 1e ). DNIkBa H157 xenografts grew to a larger size (450+60 mm 3 , n=38) over a shorter time frame compared to WT H157 xenografts (223+20 mm 3 , n=38) with growth dierences reaching statistical signi®cance (P50.005) at day 17 that persisted until the end of the experiment. At day 31, the DNIkBa H157 xenografts reached a size of 2426+658 mm 3 while WT H157 xenografts had grown to 1233+218 mm 3 (P50.005). The aggressive tumor growth characteristic of DNIkBa H157 xenografts is not simply the result of a faster growth rate compared with WT H157 cells. In fact, in vitro growth curves suggest that DNIkBa H157 cells grow with a comparable but somewhat slower doubling time relative to WT H157 cells (Figure 1f ).
NF-kB is required for genotoxin but not paclitaxel-induced apoptosis
Treatment of WT H157 cells with 300 nM doxorubicin resulted in 32% apoptosis over 48 h. This is inhibited by almost 50% in DNIkBa H157 cells with an apoptotic index of 17% after a similar treatment with doxorubicin (not shown). This is comparable apoptotic suppression as was seen with 100 mM etoposide treatment ( Figure 1a) . However, to determine the speci®city of NF-kB in genotoxin induced apoptosis, we treated cells with the microtubule toxin paclitaxel. Paclitaxel induces apoptosis primarily through phosphorylation and subsequent inactivation of Bcl-2. The phosphorylation renders Bcl-2 unable to sequester proapoptotic Bcl-2 family members such as Bax which induce mitochondria release of cytochrome c (Srivas- Strobel et al., 1996) . Figure 2a shows the response of WT and DNIkBa H157 cells exposed to 30 nM and 300 nM paclitaxel for 24 h. Fifty to 52% of WT H157 cells are apoptotic after 24 h for both paclitaxel doses while 40% and 46% of DNIkBa H157 cells are apoptotic after 30 and 300 nM paclitaxel treatment, respectively. Paclitaxel-induced apoptosis was not signi®cantly dependent on NF-kB activation, whereas loss of NF-kB activation in DNIkBa expressing cells resulted in signi®cant resistance to both etoposide and doxorubicin.
In agreement with the in vitro results, analysis of xenografts in nude mice indicated sensitivity of WT H157 and DNIkBa H157 cell-derived tumors to treatment with paclitaxel ( Figure 2b ,c). The result with paclitaxel is in sharp contrast to the etoposide resistance of DNIkBa H157 cells in vitro as well as in xenografts. Wild type H157 xenograft growth is suppressed with etoposide treatment with a separation of growth curves reaching statistical signi®cance by day 21 (Figure 2d ). In contrast, DNIkBa xenografts are resistant to etoposide ( Figure 2e ). Despite treatment with etoposide, DNIkBa xenografts continue to grow at the same rate as untreated DNIkBa expressing tumors. These ®ndings indicate that inhibition of NFkB function in H157 cells results in a more aggressive tumor that is refractory to treatment with etoposide, similar to the anti-apoptosis and chemo-resistance of DNIkBa expressing H157 cells assayed in vitro ( Figure  1a ).
Etoposide induces surface expression of TRAIL and DR5
Increased cell surface expression of TRAIL is a general response to etoposide in both lung and breast epithelium ( Figure 3 ). Using non-transformed, nonimmortalized primary human airway epithelium (HAEC) and primary human mammary epithelium (HMEC) in conjunction with A549 lung adenocarcinoma, MDA-231 breast carcinoma, and ZR-75-1 breast caricinoma cells, we measured cell surface expression of TRAIL in response to 24 h of 100 mM etoposide. All ®ve unstimulated cell lines had no detectable surface TRAIL expression (left column). Reproducible increases of 1.6 ± 3.1-fold (middle and right column) were demonstrated after etoposide treatment. Bar graphs display the relative¯uorescence for each cell line with and without etoposide (right column).
The chemo-resistance of DNIkB expressing H157 cells in vitro and in vivo indicates a major change in apoptotic potential resulting from loss of NF-kB signaling. We had previously shown that TRAIL and DR5 expression in dierent cell types was NF-kB , therefore, we predicted that a loss in the surface expression of TRAIL or its death promoting receptors, DR4 and DR5, could account for the loss in genotoxin sensitivity we observed in DNIkB expressing H157 cells. To test this hypothesis, WT and DNIkBa H157 cells were treated with 100 mM etoposide for 24 h and subjected to¯ow cytometric analysis for measurement of DR4, DR5 and TRAIL cell surface expression. Figure 4a and b depict the surface expression of DR4 in WT H157 and DNIkBa H157 cells with and without etoposide treatment. Figure 4c shows this data in bar graph format in order to display the relative DR4 expression with and without etoposide treatment of cells. WT H157 cells demonstrate DR4 surface expression of 15.3+0.6 and 18.1+1.7 (n=3, P50.05) times greater than background with and without etoposide treatment, respectively. No signi®cant dierence in DR4 surface expression is seen in DNIkBa H157 cells, which demonstrate comparable DR4 surface expression ratios of 12.2+0.9 and 17.0+0.5 (n=3, P50.05) with and without etoposide treatment, respectively. The levels of DR4 expression correlates with RNase protection assays measuring DR4 transcript (data not shown). Although DR4 surface expression levels decrease in both WT and DNIkBa H157 cells in response to etoposide, the magnitude of change being less than 50% stands in direct contrast to DR5.
DR5 surface expression increases with etoposide treatment in WT H157 cells, and this induction of surface expression is inhibited in DNIkBa H157 cells (Figure 4d , e, and f). Basal levels of DR5 in WT H157 cells drop from a relative surface expression of 13.1+0.5 in wild type to 9.2+0.3 (n=3, P50.001) in DNIkBa H157 cells. More importantly, etoposide induced expression of DR5 with a surface expression ratio of 24.5+2.3 in wild type cells drops signi®cantly to 6.8+0.2 (n=3, P50.0005) in DNIkBa H157 cells (Figure 4f) . TRAIL surface expression in WT H157 cells treated with etoposide is also up-regulated as seen in Figure 4g and i. While WT H157 cells treated with etoposide induce surface expression of TRAIL 1.6-fold, this induction is absent in DNIkBa H157 cells (Figure 4h and i). The surface expression of TRAIL is relatively low but highly reproducible in its induction by etoposide (n=3, P50.01). Etoposide therefore induces increased surface expression of TRAIL and one of its death promoting receptors, DR5. This is a NF-kB dependent response, as DNIkBa H157 cells lack the ability to increase the surface expression of both TRAIL and DR5 in response to etoposide.
Profiling the genotoxin response of H157 cells NF-kB activation in several cell types appears to promote cell survival not apoptosis as observed with H157 cells (Baeuerle and Baltimore, 1996; Basu et al., 1998; Lin et al., 1998) . The expression of the inhibitors of apoptosis, or IAPs, inhibit speci®c caspases and have been shown to be positively regulated by NF-kB. Thus, in addition to TRAIL and DR5, NF-kB is capable of regulating pro-survival genes. To de®ne NF-kB regulated genes that contribute to pro-or anti-apoptotic signaling in response to genotoxins in cancer, gene pro®ling was conducted with total RNA isolated from WT and DNIkBa H157 cells. H157 cells stably expressing DNIkBa and DNIkBa-adenovirus infection of H157 cells were used for analysis with similar results in pro®ling the gene expression response to etoposide treatment. Hu6800 Aymetrix gene chips compared mRNA levels of 7129 genes between WT and DNIkBa expressing H157 cells treated for 0, 12, or 24 h with either 100 mM etoposide or DMSO treated control cells. Using this approach we were able to de®ne genes whose expression is dependent on NF-kB transcriptional activity in the presence or absence of etoposide. Figure 5 presents the list of genes regulated in a NFkB dependent mechanism in response to etoposide. Database review revealed that 33% (17/52) of the 52 genes identi®ed as NF-kB-dependent have been previously identi®ed as regulated by NF-kB. This percentage is likely higher as many of the genes have no information regarding the role of NF-kB in controlling their expression. From a total of 52 genes dependent on NF-kB activation for regulation of their expression, 13 etoposide inducible genes were readily identi®ed that have previously characterized functions that can clearly promote or inhibit apoptosis ( Figure  5a) . The values listed in Figures 5a and b indicate the etoposide induced fold change in WT cells that was absent in DNIkBa expressing cells. Two etoposide induced genes, A20 (Cooper et al., 1996; Krikos et al., 1992) and manganese superoxide dismutase (SOD2) are well de®ned in their regulation by NF-kB. Three genes having strong anti-apoptotic functions, the inhibitors of apoptosis (cIAP-1, cIAP-2 and XIAP), are induced by etoposide treatment. Forkhead FREAC-1 is a lung speci®c forkhead transcription factor and whose mRNA was increased sixfold in response to etoposide in an NF-kBdependent mechanism (Hellqvist et al., 1996; Mahlapuu et al., 1998; Pierrou et al., 1994) . Speci®c forkhead transcription factors have been implicated in regulating pro-apoptotic gene expression including Fas ligand (Brunet et al., 1999) . Trefoil factor is a cytokine known to promote cell survival (Chen et al., 2000; Suemori et al., 1991; Taupin et al., 2000; Thim, 1989) , as is cell adherence to the extracellular matrix protein, ®bronec-tin (Sakai et al., 2001; Zhang et al., 1995) . The expression of both trefoil factor and ®bronectin was NF-kB dependent and markedly inhibited in response to etoposide. Overall, of the 13 genes whose function has been clearly associated with survival and/or apoptosis, 11 were up-regulated and two downregulated in response to etoposide in a NF-kB dependent mechanism.
Granted many other genes are regulated in response to etoposide (Figure 5b ) or by NF-kB independent of etoposide ( Figure 5c ) that may regulate cell survival. In addition, genes not represented in the array may have signi®cant roles in the response to genotoxin. Despite these limitations, the gene pro®les identi®ed in Figure 5a argue for an orchestrated response of cells exposed to etoposide that promotes survival versus the paracrine death response mediated by TRAIL. Genotoxins such as etoposide, in addition to inhibiting DNA replication, also generate oxygen radicals that cause cellular damage and can themselves induce apoptosis (Verhaegen et al., 1995) . Reactive oxygen species activate NF-kB and a compensatory SOD2 expression results in oxygen radical metabolism and protection from further cellular damage. A20 inhibits receptor activation of NF-kB and is well characterized in its ability to inhibit TNF-induced apoptosis (Opipari et al., 1992) . A20 expression would be predicted to protect cells from genotoxins by suppressing death receptor signaling. The strong induction of cIAP-1 and cIAP-2 would inhibit the caspases that drive cells down the apoptotic pathway (Chu et al., 1997; Wang et al., 1998) . In contrast, the induction of TRAIL and DR5 would stimulate caspases that drive the apoptotic response. Induction of TNF receptor expression may also contribute to a pro-apoptotic response. Clearly, the NF-kB-dependent response to etoposide is complex and shows a response that allows cells to survive or die. NF-kBdependent gene expression in response to etoposide is neither pro-survival nor anti-survival but rather allows a decision process for cell fate.
Validation of mRNA expression profiling
The NF-kB dependent changes in mRNA expression were con®rmed for four genes, two with clear functions in apoptosis and two in controlling cell cycle or signaling. cIAP-1 and 2, cyclin D2 and MEK5c expression was monitored by relative reverse transcription PCR (RT ± PCR). Results shown in Figure 6 depicts the fold-changes in RNA levels by Sybr-green RT ± PCR analysis of total RNA harvested after 24 h treatment with etoposide in WT and DNIkBa H157 cells. RNA concentrations were controlled with internal 18S RNA standardized curves. The induction of cIAP-1 and cIAP-2 was blocked in DNIkBa H157 cells compared with WT H157 such that WT cells had 11+3.7 and 37+21-fold higher levels of cIAP-1 and cIAP-2 respectively. Changes in expression of cyclin D2 and MEK5c were similarly con®rmed, indicating the general validity of the expression pro®les shown in Figure 5 .
IAP expression promotes H157 cell survival
Because IAPs are strongly induced by genotoxin treatment, we chose to examine whether expression of the IAP proteins cIAP-1 and cIAP-2 could inhibit etoposide-induced apoptosis. Expression vectors containing the sequences for cIAP-1 and cIAP-2 were generated in IRES vectors encoding green¯uorescent protein (GFP) for selection by¯ow cytometry. H157 cell populations selected for GFP expression demonstrated overexpression of cIAP-1 and cIAP-2 greater than 10-fold compared with H157 cells harboring empty IRES-GFP vector and wild type H157 cells as determined by Sybr-green RT ± PCR (data not shown). Figure 7 shows the results of apoptosis assays for the various H157 cell lines when exposed to 100 mM etoposide for 24 h. Wild type H157 cells and H157 cells harboring empty vector had 23+1.2% and 21+1.4% of the cell population apoptotic following etoposide treatment, respectively. Overexpression of cIAP-1 or cIAP-2 resulted in a signi®cantly (P50.05) inhibited apoptotic response to etoposide with 10+2.8% and 12+1.8% of the cells undergoing apoptosis, respectively. Thus, increased expression of IAPs results in a 50% diminution in apoptosis in H157 cells treated with etoposide. The results indicate that induction of IAPs would have a survival function in response to etoposide. Etoposide therefore induces expression of several genes that in¯uence cell survival including TRAIL and its death receptor, DR5, and IAPs. The cumulative action of these proteins dictate cell survival. Figure 5 Gene-pro®ling identi®es NF-kB as a regulator of both pro-and anti-apoptotic signaling. Only genes whose expression was similar across all three time points and whose fold change was two or greater by both GeneChip and GeneSpring mathematical algorithms are included in the ®nal gene lists. (a) Gene pro®ling identi®es important apoptotic mediators whose expression is dependent upon NF-kB in the presence of etoposide. The asterisk on TRAIL and DR5 indicate they are not on the Hu6800 gene chip. RNase protection assays with probes for TRAIL and DR5 were performed on the RNA samples and quantitated in response to etoposide. (b) Etoposide also altered expression of other genes in an NF-kB dependent manner. (c) NF-kB also regulates genes independent of etoposide. Individual analysis of gene pro®les with GeneChip and GeneSpring software identi®es additional NF-kB dependent proteins with both pro-and anti-apoptotic roles in response to genotoxin insult Suppression of TRAIL death receptor signaling leads to chemo-resistance Induction of TRAIL expression in response to genotoxins strongly correlates with the magnitude of apoptosis that is observed in normal lung and breast epithelium and carcinoma (Figure 8a ). Cell surface TRAIL expression correlates with the apoptotic response to etoposide for primary human airway epithelium, H157 lung squamous carcinoma cells, A549 lung adenocarcinoma cells, ZR-75-1, and MDA-231 human breast adenocarcinoma cells. To test the prediction that cell surface TRAIL expression is an important autocrine or paracrine response to genotoxin-induced cell death, we stably expressed in H157 cells the GPI-linked decoy receptor, DcR1, which binds TRAIL but does not signal caspase activation (Sheridan et al., 1997) . DcR1 expression functions to bind TRAIL and eectively block TRAIL-induced apoptosis. The etoposide dose response curves seen in Figure 8b demonstrate that as the dose of genotoxin increases, the degree of apoptosis also increases in WT H157 cells. With etoposide doses ranging from 1 ± 100 mM with 48 h treatment, WT H157 cells displayed apoptotic responses ranging from 18 ± 52%. Two separate stable clones of H157 cells expressing DcR1, as con®rmed by¯ow cytometry analysis of cell surface expression (data not shown), suppress etoposide-induced apoptosis relative to control H157 cells. H157 cells expressing DcR1 suppress etoposide induced apoptosis rates by greater than 50% to levels of 6 ± 24% over the same dose range used with WT H157 cells (n=3, P50.05 at all doses). DcR1 expression has a strong protective eect against etoposide induced cell death, consistent with a signi®cant role for TRAIL in the death response and diminished TRAIL signaling in chemo-resistance to etoposide. Figure 8c demonstrates that DcR1 protects against doxorubicin induced apoptosis as well. WT H157 cells increased from 4+1% to 35+3% apoptosis with 300 nM and 37+2% apoptosis with 1 mM doxorubicin treatment. Two separate stable clones of H157 cells expressing DcR1 suppressed the doxorubicin induced apoptosis at 300 nM (22+0% for clone 1, 11+4% for clone 2, P50.05 vs WT) and at 1 mM (20+1% for clone 1, 16+4% for clone 2, P50.05 vs WT). A similar eect of DcR1 is seen in MDA-231 breast adenocarcinomas (not shown), demonstrating the protective role of DcR1 against genotoxins is a general function of the decoy receptor and not a unique response in H157 cells. The protective eect of DcR1 expression is selective for genotoxins such as etoposide and doxorubicin and is not seen with paclitaxel-induced H157 cell death (Figure 8d ), con®rming a signi®cant role for TRAIL expression in the apoptotic response to speci®c genotoxins but not microtubule toxins. Paclitaxel induced apoptosis to similar levels in WT and two separate DcR1 clones; 30 nM induced 52+6% in WT vs 58+1% in clone 1 vs 47+1% in clone 2 while 300 nM induced 52+4% in WT vs 62+1% in clone 1 vs 51+5% in clone 2.
Discussion
Two dierent but converging experimental lines of study are de®ning the importance of TRAIL-mediated death signaling in cancer. Several studies have begun to de®ne mutations in the death receptors for TRAIL in dierent cancers. In metastatic breast cancer , head and neck squamous cell cancer (Fisher et al., 2001; Ozoren et al., 2000; Pai et al., 1998) , lung cancer (Fisher et al., 2001; Lee et al., 1999; Wu et al., 2000) , and non-Hodgkin's lymphoma mutations have been de®ned in the death receptors for TRAIL. In numerous other cancers changes in the expression pro®le of TRAIL death receptors has also Figure 6 Gene pro®ling validations con®rm the importance of endogenous apoptotic mediators in genotoxin-induced apoptosis. To further validate identi®ed gene pro®les, Sybr-green relative RT ± PCR was performed with total RNA obtained from WT H157 and DNIkBa H157 cells using primers corresponding to cyclin D2, cIAP-1, cIAP-2 and MEK5c. The graph represents the mean RNA fold change between WT H157 and DNIkBa H157 cells treated with etoposide from two independent experiments performed in triplicate while error bars are s.e.m. been de®ned. Cumulatively, these studies indicate that expression or function of receptors that signal TRAILinduced apoptosis is altered at frequencies approaching 50% in some cancers. Although the signi®cance of these mutations is presently unclear, their frequency and potential survival advantage suggests they may contribute to tumorigenesis and possibly metastasis. TRAIL also has been shown to be decreased in oligodendrogliomas (Nakamura et al., 2000) . Our work and that of others are de®ning an involvement of a paracrine action for TRAIL-induced apoptosis in chemotherapy (Altucci et al., 2001; Gibson et al., 2000) . Paracrine TRAIL-induced apoptosis is important for genotoxins like etoposide and doxorubicin but less important for the apoptotic response to microtubule toxins. Mutations that inhibit TRAIL receptor signaling or diminish TRAIL expression should promote resistance to chemotherapy.
What is the evidence that a paracrine TRAIL-induced apoptosis response is important in chemotherapy? Flow cytometric analysis clearly demonstrates that etoposide and doxorubicin stimulate cell surface expression of TRAIL in normal epithelium and multiple epitheliaderived carcinoma cell lines. The use of a soluble DR4:Fc fusion protein that binds TRAIL eectively suppresses genotoxin-induced apoptosis . This ®nding demonstrates that surface TRAIL expression contributes to genotoxin-induced cell death. Similarly, reovirus-induced apoptosis involves expression of TRAIL in epithelial-derived tumor cell lines that is inhibited by DR4:Fc fusion proteins or anti-TRAIL antibodies (Clarke et al., 2000) . In both studies the use of TNFa or Fas ligand protein traps or antibodies did not inhibit cell death, demonstrating the speci®city of TRAIL in both genotoxin and virus-induced apoptosis. We have also used an alternative strategy, namely the expression of the TRAIL decoy receptor, DcR1, to inhibit genotoxin but not paclitaxel-induced apoptosis. DcR1, DR4:Fc and anti-TRAIL antibody suppression of genotoxin-induced apoptosis all demonstrate the importance of cell surface expression of TRAIL in speci®c apoptotic responses in epithelial-derived carcinomas. Interestingly, both geno- toxin-and reovirus-induced expression of TRAIL is dependent on functional NF-kB signaling and inhibited by DNIkB. It was also recently shown that retinoic acidinduced apoptosis of acute promyelocytic leukemia cells is mediated by a paracrine TRAIL action (Altucci et al., 2001) . Cumulatively, the ®ndings indicate paracrine TRAIL-induced apoptosis is a major contributing mechanism to the action of dierent drugs and viralinduced apoptosis of tumor cells.
Pro®ling the NF-kB-dependent response to etoposide demonstrates the induction of many genes including TRAIL and the IAPs. The IAPs are markedly induced in response to genotoxins and have the ability to signi®cantly inhibit etoposide-mediated cell killing. We did not observe a signi®cant change in expression of Bcl-X L or any other Bcl-2 family member in H157 cells. Furthermore, the use of paclitaxel, a microtubule toxin that induces apoptosis primarily through phosphorylation and inactivation of Bcl-2 (Srivastava et al., 1999; Strobel et al., 1996) , did not depend on NF-kB activity for initiating programmed cell death. At least in H157 lung squamous carcinoma cells, our studies would argue that NF-kB-dependent IAP expression is a signi®cant mechanism for the survival function of NF-kB signaling. These ®ndings indicate that activation of NF-kB in response to genotoxins stimulates a TRAIL death response and an IAP survival response. In dierent cancers, the magnitude of TRAIL expression for paracrine-mediated apoptosis versus IAP expression for survival is going to in¯uence the chemo-sensitivity of the tumor. For example, tumor cells that lose the TRAIL paracrine response may be particularly chemo-resistant. Clinically, the administration of recombinant TRAIL concurrent with genotoxin based chemotherapy may help tilt the balance of NFkB mediated signaling towards tumor cell apoptosis.
Materials and methods
Generation of stable clones
The cDNA for DNIkBa was excised from a CMV hIkBa 32S/32A vector and cloned into the HindIII/XbaI sites of pcDNA3.1(+). H157 cells were transfected with lipofectamine (Gibco BRL) and selected for neomycin resistance. Clones were screened for IkBa over-expression by Western blot and gel shift assay for loss of NF-kB DNA binding with nuclear extracts from cells treated with and without PMA. DcR1 stable cell lines were similarly generated with pcDNA3.1(+)/DcR1. After the clones grew to acceptable numbers,¯ow cytometry for surface expression of DcR1 was performed to verify G418 resistant clones over-expressing DcR1, cIAP-1, cIAP-2, and cIAP-1-AS stable clones were generated by cloning into the EcoR1 site of IRES vector (Clontech), selecting for G418 resistance, and performinḡ ow cytometry to con®rm GFP expression. IAP expression was con®rmed by RT ± PCR.
Acridine orange staining
H157 and DNIkBa H157 cells were treated with 100 mM etoposide, 30 nM paclitaxel, 300 nM paclitaxel, or 1 mM doxorubicin. At the given time points, 50 ml of a PBS solution containing 100 mg/ml acridine orange and 100 mg/ml ethidium bromide was added to pelleted cells. Cells were visualized on ā uorescent inverted microscope using a 406LWD lens and a high pass FITC ®lter to allow for nuclear visualization. At least 300 cells per plate were counted in a double blinded fashion. Only cells with both condensed chromatin and membrane blebbing were scored as apoptotic.
Flow cytometry for detection of surface expressed TRAIL, DR4, DR5 and DcR1
Anti-TRAIL, anti-DR4, anti-DR5, and anti-DcR1 antibodies were a kind gift from Immunex corporation. Flow cytometry was performed as previously described (Sedger et al., 1999) . Cells were analysed using a FACScan¯ow cytometer (Becton Dickinson) running Cell Quest Software (Becton Dickinson).
Western blotting
Western blotting was performed as previously described . IkBa antibody was used at a concentration of 1 : 500 (Santa Cruz).
Xenograft implantation
1610
6 cells per 100 ml 16PBS and 100 ml growth factor reduced matrigel were injected on athymic nude mice posterior¯anks. Tumor volumes were measured twice a week, and tumor volumes were calculated using the formula volume=length 2 *width*p/6. Treated mice were given 15 mg/ kg etoposide or 15 mg/kg paclitaxel intraperitoneally on days 7, 14 and 21.
Affymetrix gene chip profiling
Total RNA was isolated per manufacturer's recommendation with RNAzol (Tel-Test) from WT H157 cells and DNIkBa H157 cells treated for 0, 12, or 24 h with 100 mm etoposide (Sigma chemicals). Probes were generated per Aymetrix recommendations. Hu6800 probe arrays were then read with an argon laser in the HP GeneArray TM Scanner.
Gene profile analysis
Raw data was normalized separately in both GeneChip and GeneSpring to maximize sensitivity and speci®city by using two dierent mathematical algorithms. All genes identi®ed in the lists had a twofold or greater change in expression between WT H157 and Time zero, 12 h, and 24 h time points with or without etoposide treatment were treated as replicate experiments. Only genes whose expression pro®les were consistent across these time points were included in the ®nal gene lists. Further stringency was applied by excluding genes identi®ed as absent in both groups by GeneChip.
Sybr green RT ± PCR
RNA was isolated with RNAzol (Tel-Test). RNA samples were additionally treated with DNAse for 15 min at 378C. PCR primers for ampli®cation were selected utilizing Primer Express TM software (PE Applied Biosystems). All samples were normalized utilizing 18 s rRNA as an endogenous control. Each ampli®cation was replicated in triplicate with total RNA isolated from three separate experiments.
